Shire Acquires Baxalta in $32 Billion Deal
Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.
Shire and Baxalta have announced $32 billion agreement under which Shire will combine with Baxalta, creating a company with the top rare diseases platform in revenue and pipeline depth, the companies reported in a Jan. 11, 2016 press statement. The new company is projected to achieve annual revenues of $20 billion by 2020.
Shire reports that the combined companies will have products in growing franchises in hematology; immunology; neuroscience; lysosomal storage diseases; gastrointestinal/endocrine; hereditary angioedema; and oncology; as well as a late-stage ophthalmics pipeline.
Baxalta shareholders will hold approximately 34% ownership in the combined company. The parties expect the transaction to close mid-2016.
Source: Shire
